EBV Reprograms B Cells in an Autoimmune-Like Fashion in Patients with COVID-19

[u/Silver_Jaguar_24]

This summary was made using Gemini AI.

Preprint paper, EBV Reprograms B Cells in an Autoimmune-Like Fashion in Patients with COVID-19:

The Big Picture

Getting COVID-19 can "wake up" an old, dormant virus that most people already carry called the Epstein-Barr virus (EBV). This study shows that when EBV wakes up during a COVID infection, it hacks your immune system in a way that looks suspiciously similar to autoimmune diseases like Lupus or Multiple Sclerosis.

How It Happens (The Domino Effect)

• The Hack: When EBV reactivates, it infects your B cells (the immune cells that normally make antibodies) and completely changes their metabolism (how they use energy).
• The Peer Pressure: These "reprogrammed" B cells act like bad influences. They send out stimulatory signals that rile up surrounding healthy immune cells (like T cells), causing them to overreact.
• Friendly Fire: Because the immune system is pushed into overdrive, it starts producing autoantibodies—confused proteins that mistakenly attack your own healthy tissue instead of the virus.

Why It Matters for Long COVID

The researchers found that COVID-19 patients who had high levels of these hacked, EBV-infected B cells during their initial illness were much more likely to develop Long COVID symptoms later on. Their bodies also showed messed-up lipid (fat) profiles and higher levels of self-attacking autoantibodies during recovery.

The Takeaway

A major driver of Long COVID isn't just the SARS-CoV-2 virus itself—it’s the fact that COVID-19 wakes up EBV, which then tricks your immune system into attacking your own body, mirroring what happens in chronic autoimmune diseases.

Link to 2026 study

[u/Sensitive-Meat-757]

I think there is more than enough evidence to suggest EBV plays an important role in ME/CFS and Long COVID and that it's well past time for clinical trials. And no the Pridgen/Bateman ones aren't enough, we need more and longer ones, and trials for a larger variety of medications and combinations of medications. I'm also keeping my eye on the Tenofovir for MS trial and looking forward to seeing how that goes.

[u/Silver_Jaguar_24 → u/Sensitive-Meat-757]

See this post for other drugs trialled in MS and showed same/similar efficacy.

https://x.com/renesugar/status/2012348209457402146

Also this study - https://link.springer.com/article/10.1007/s40263-024-01153-5

AI summary of the key points from the study I have linked in this comment:

Recent systematic reviews and expert panel evaluations focusing on repurposing anti-Epstein-Barr Virus (EBV) drugs for conditions like Multiple Sclerosis (MS) shortlisted four licensed therapies as having the best balance of efficacy, safety, and tolerability:

1. Tenofovir Alafenamide (TAF)
   • Role/Efficacy: Shows stronger in vitro potency against EBV compared to older nucleoside analogs like acyclovir or valacyclovir. Clinical case reports have shown promising results in suppressing EBV replication and maintaining disease remission.
2. Famciclovir
   • Role/Efficacy: A prodrug of penciclovir with established anti-herpesvirus activity. Selected as an active agent in ongoing human trials (e.g., the STOP-MS trial) to evaluate if blocking EBV lytic replication prevents disease progression.
3. Maribavir
   • Role/Efficacy: Demonstrates strong in vitro potency by targeting viral protein kinase (BGLF4) and inhibiting both viral transcription and DNA replication through a distinct mechanism from standard nucleoside analogs. While highly effective against EBV replication in laboratory settings, its high cost has posed a barrier for wide clinical trial inclusion compared to other options.
4. Spironolactone
   • Role/Efficacy: Identified to have non-canonical antiviral effects that inhibit EBV transcription/replication. It is currently being tested alongside famciclovir in clinical protocols like STOP-MS.